Skip to main content

CCTG related presentations at ASH 2024

CCTG related presentations at ASH 2024
Listed are the CCTG related presentations at the 66th American Society of Hematology Annual Meeting and Exposition, December 7-10, 2024 in San Diego, California. 

ALC1
Sciambi A, Mendoza D, Thompson K, Beppu LW, Geller B, Krishnan I, Nousheen L, Wang S, Murphy C, Radich JP, Druley TE. Single-Cell Multi-Omic Analysis of AML MRD Reveals Differences in Clonal Architecture between Relapse and Non-Relapse Cases. 66th American Society of Hematology Annual Meeting and Exposition. Blood 144 [Supplement 1], 1568-1568. 2024.
 
Liu VM, Othus M, Ries RE, Naru J, Pogosova-Agadjanyan EL, Appelbaum FR, Beppu LW, Chauncey TR, Erba HP, Godwin JE, Fitzgibbon M, Fang M, Lee SC, Moseley AB, Radich JP, Willman CL, Wu F, Meshinchi S, Stirewalt DL. Evaluation of ELN2022 Risk Stratification in NPM1 Mutated AML: A Study from the Fred Hutch and SWOG. 66th American Society of Hematology Annual Meeting and Exposition. Blood 144 [Supplement 1], 4309-4309. 2024.
 
ALC2
Stone RM, Yin J, Mandrekar SJ, Benner A, Saadati M, Galinsky IA, Sanford BL, Teske R, Geyer SM, Prior T, Amadori S, Appelbaum FR, Brandwein J, Döhner K, Ehninger G, Ganser A, Klisovic RB, Krauter J, Marcucci G, Medeiros B, Niederwieser DW, Sanz MA, Schlenk RF, Serve H, Sierra J, Tallman MS, Wei AH, de Witte TJM, Thiede C, Döhner H, Larson RA. 10 Year Follow-up of CALGB 10603/Ratify: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years. 66th American Society of Hematology Annual Meeting and Exposition. Blood 144 [Supplement 1], 218-218. 2024.
 
ALC4
Podoltsev NA, Sun Z, Litzow MR, Paietta E, Roberts KG, Zhang Y, Racevskis J, Lazarus HM, Rowe JM, Arber DA, Wieduwilt MJ, Liedtke M, Bergeron J, Wood BL, Zhao Y, Wu G, Chang T-C, Zhang W, Pratz KW, Dinner SN, Frey N, Gore SD, Bhatnagar B, Atallah EL, Uy GL, Jeyakumar D, Lin TL, Willman CL, DeAngelo DJ, Patel SB, Elliott MA, Advani AS, Tzachanis D, Vachhani P, Roy R, Sharon E, Little R, Erba H, Stone RM, Mullighan CG, Tallman MS, Luger S, Mattison RJ. Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial. 66th American Society of Hematology Annual Meeting and Exposition. Blood 144 [Supplement 1], 4211-4211. 2024.
 
Liedtke M, Sun Z, Litzow MR, Mattison RJ, Paietta E, Roberts KG, Zhang Y, Racevskis J, Lazarus HM, Rowe JM, Arber DA, Bergeron J, Wood BL, Zhao Y, Wu G, Chang T-C, Zhang W, Pratz KW, Dinner SN, Frey N, Gore SD, Bhatnagar B, Atallah EL, Uy GL, Jeyakumar D, Lin TL, Willman CL, DeAngelo DJ, Patel SB, Elliott MA, Advani AS, Tzachanis D, Vachhani P, Bhave R, Sharon E, Little R, Erba HP, Stone RM, Luger S, Mullighan CG, Tallman MS, Wieduwilt MJ. Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial. 66th American Society of Hematology Annual Meeting and Exposition. Blood 144 [Supplement 1], 779-779. 2024.
 
 
ALC6
DeAngelo DJ, Yin J, Advani AS, Luger S, Fulcher J, Liedtke M, Uy GL, Dinner SN, Wilde L, Luskin MR, Saygin C, Postich E, Fulton N, Harvey RC, Perez Burbano GE, Teske R, Erba HP, Litzow MR, Stone RM, Stock W. Addition of Inotuzumab to a Pediatric Inspired Chemotherapy Regimen in Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia: Findings from the Alliance A041501 Phase 3 Randomized Trial. 66th American Society of Hematology Annual Meeting and Exposition. Blood 144 [Supplement 1], 308-308. 2024.